This study is a pilot, multi-center, observational retrospective-prospective study, with two different Parts, as follows:
1. Part 1(retrospective and prospective part): to evaluate efficacy and safety of switching to BIC/FTC/TAF in People living with HIV (PWH) who previously failed CAB/RPV LAI in the last three years and received in the last three years boosted PI since any INSTI mutations were detected on RNA and/or DNA through NGS at failure
2. Part 2 (prospective part only): to evaluate efficacy and safety of switching directly to BIC/FTC/TAF in PWH who failed CAB/RPV LAI without any RAMs on RNA and/or DNA through NGS considered of potential relevance for bictegravir
Inclusion Criteria:
* PWH with age \>18 years
* PWH with a confirmed virological failure on CAB/RPV LAI in the last three years
* PWH without RAMs versus FTC and TAF
Study population: 30 subjects failing CAB/RPV LAI will be included in the study
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-26.